DE60329116D1 - Herstellung von homotrimeren fusionsproteinen - Google Patents

Herstellung von homotrimeren fusionsproteinen

Info

Publication number
DE60329116D1
DE60329116D1 DE60329116T DE60329116T DE60329116D1 DE 60329116 D1 DE60329116 D1 DE 60329116D1 DE 60329116 T DE60329116 T DE 60329116T DE 60329116 T DE60329116 T DE 60329116T DE 60329116 D1 DE60329116 D1 DE 60329116D1
Authority
DE
Germany
Prior art keywords
seq
amino acid
acid residues
trimerizing
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60329116T
Other languages
English (en)
Inventor
James W West
Cameron S Brandt
Stephen R Jaspers
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zymogenetics Inc
Original Assignee
Zymogenetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zymogenetics Inc filed Critical Zymogenetics Inc
Application granted granted Critical
Publication of DE60329116D1 publication Critical patent/DE60329116D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DE60329116T 2002-10-11 2003-10-10 Herstellung von homotrimeren fusionsproteinen Expired - Lifetime DE60329116D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41780102P 2002-10-11 2002-10-11
PCT/US2003/032878 WO2004033486A2 (en) 2002-10-11 2003-10-10 Production of homotrimeric fusion proteins

Publications (1)

Publication Number Publication Date
DE60329116D1 true DE60329116D1 (de) 2009-10-15

Family

ID=32094093

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60329116T Expired - Lifetime DE60329116D1 (de) 2002-10-11 2003-10-10 Herstellung von homotrimeren fusionsproteinen

Country Status (8)

Country Link
US (2) US20050009149A1 (de)
EP (1) EP1558278B1 (de)
JP (1) JP2006502715A (de)
AT (1) ATE441428T1 (de)
AU (1) AU2003284260B2 (de)
CA (1) CA2501459A1 (de)
DE (1) DE60329116D1 (de)
WO (1) WO2004033486A2 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1885753T1 (sl) 2005-06-03 2011-12-30 Ares Trading Sa Proizvodnja rekombinantnega il-18 vezavnega proteina
ES2415890T3 (es) 2005-09-09 2013-07-29 Zymogenetics, Inc. Procedimiento de preparación de proteínas triméricas
ES2524553T3 (es) 2008-06-17 2014-12-10 Apogenix Gmbh Receptores multiméricos de TNF
US9537650B2 (en) * 2009-12-15 2017-01-03 Microsoft Technology Licensing, Llc Verifiable trust for data through wrapper composition
RU2699007C2 (ru) 2013-02-18 2019-09-02 Ведженикс Пти Лимитед Молекулы, связывающие лиганды, и их применение
KR20180063885A (ko) * 2015-09-24 2018-06-12 더 유니버시티 오브 노쓰 캐롤라이나 엣 채플 힐 전이 감소를 위한 방법 및 조성물
EP4146684A2 (de) 2020-05-08 2023-03-15 Alpine Immune Sciences, Inc. April- und baff-hemmende immunmodulatorische proteine mit und ohne t-zell-hemmendes protein und verfahren zur verwendung davon

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2239303A1 (en) * 1995-12-22 1997-07-03 Somatogen, Inc. Globins containing binding domains
US5969102A (en) * 1997-03-03 1999-10-19 St. Jude Children's Research Hospital Lymphocyte surface receptor that binds CAML, nucleic acids encoding the same and methods of use thereof
JP2002540384A (ja) * 1999-02-11 2002-11-26 ゼンコー 構造ベースでの薬効物質スクリーニング法
IL145676A0 (en) * 1999-04-12 2002-06-30 Genentech Inc Tumor necrosis factor homologs and nucleic acids encoding the same
ES2267593T3 (es) * 2000-02-16 2007-03-16 Genentech, Inc. Anticuerpos anti-april y celulas hibridomas.
AU4541101A (en) * 2000-03-02 2001-09-12 Xencor Inc Design and discovery of protein based tnf-alpha variants for the treatment of tnf-alpha related disorders
CA2408617A1 (en) * 2000-05-12 2001-11-22 Amgen Inc. Methods and compositions of matter concerning april/g70, bcma, blys/agp-3, and taci
KR100436089B1 (ko) * 2000-07-06 2004-06-14 설대우 분비성 재조합 트라이머형의 트레일 단백질 생산을 위한 디엔에이 카세트, 테트라사이클린/독시사이클린-유도성아데노-관련 바이러스 벡터, 이 둘의 조합, 및 이들을이용한 유전자 치료
US6524867B2 (en) * 2000-12-28 2003-02-25 Micron Technology, Inc. Method for forming platinum-rhodium stack as an oxygen barrier
DK1436003T3 (da) * 2001-05-24 2010-03-15 Zymogenetics Inc TACI-immunoglobulin-fusionsproteiner

Also Published As

Publication number Publication date
AU2003284260A1 (en) 2004-05-04
WO2004033486A2 (en) 2004-04-22
ATE441428T1 (de) 2009-09-15
JP2006502715A (ja) 2006-01-26
CA2501459A1 (en) 2004-04-22
US20050009149A1 (en) 2005-01-13
WO2004033486A3 (en) 2004-08-05
EP1558278A2 (de) 2005-08-03
US20090192291A1 (en) 2009-07-30
EP1558278A4 (de) 2007-12-19
EP1558278B1 (de) 2009-09-02
AU2003284260B2 (en) 2010-06-03

Similar Documents

Publication Publication Date Title
ATE504599T1 (de) Zur aktivierung von rezeptoren fähige fusionspolypeptide
SG161242A1 (en) Rage fusion proteins and methods of use
DK1012274T3 (da) Dödsdomæneholdig receptor-4 (DR4: dödsreceptor 4), medlem af TNF-receptorsuperfamilien og som binder til TRAIL (Apo-2L)
WO2005047850A3 (en) Methods and compositions for producing secreted trimeric receptor analogs and biologically active fusion proteins
MX2011009810A (es) Composiciones y metodos para usar proteinas de union multiespecificas que comprenden una combinacion anticuerporeceptor.
IL180554A (en) Splice proteins are used and methods of use
NO2011003I1 (no) Dimensk fusjonsprotein bestående av de ligandbindende cfomener av de ekstacellulære deler av human type I interieukm-1 reseptor (IL-1R1) og IL-1 reseptor hjelpeprotein bundet (IL-I-RAcP) bundet i tinje til Fc-delen av humant IgG
WO2007070671A3 (en) Therapeutic methods for inhibiting tumor growth with dll4 antagonists
ATE469913T1 (de) Antagonisten des nogo-rezeptors
IS8339A (is) Mótlyf viðtaka NOGO
SG171670A1 (en) Rage fusion proteins, formulations, and methods of use thereof
PL403488A1 (pl) Zastosowanie bialka fuzyjnego TACI-immunoglobulina, bialko fuzyjne, czasteczka kwasu nukleinowego kodujaca bialko fuzyjne, kompozycja farmaceutyczna i sposób wytwarzania bialka fuzyjnego TACI-immunoglobulina
DE60329116D1 (de) Herstellung von homotrimeren fusionsproteinen
JP2009529509A5 (de)
ATE430157T1 (de) Hilfsstoff zur bildung einer amidbindung
AU2003250825A1 (en) Inhibitors of glycoprotein vi
JP2002514418A5 (de)
WO2001085782A3 (en) Fusion receptor from TNF family
ATE462727T1 (de) An menschliches roundabout bindende antikörper, polypeptide und ihre verwendung zur hemmung der angiogenese
Wiesmann et al. Ligand-binding sites in Ig-like domains of receptor tyrosine kinases
DE69939275D1 (de) Peptide, bestehend aus zwei funktionellen PTH-Domänen, die durch ein Linkermolekül verknüpft sind, und Derivate davon
ATE300611T1 (de) Auf rezeptorgrundlage arbeitende screening- verfahren für protein wechselwirkungen
JP2020536518A5 (de)
WO2005028664A3 (en) Modulation of programmed necrosis
DE69925116D1 (de) Neue, physiologisch aktive peptide und ihre verwendung.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition